Hexarelin (5mg / 10mg)

4.9 stars

$45.00$65.00

5mg
10mg

Earn up to 65 Points.

SKU: N/A Category:

Size Options: 10mg/5mg Composition: Fragment 176-191 Form: Lyophilized Powder Purity: >99% Product Code: P-FRAG176-191

Enjoy Complimentary Shipping on Orders Over $200

Receive a Free 30ml Bac Water with Orders Over $200

Discounts Available for Larger Quantities

Description

Hexarelin (5mg / 10mg)

Hexarelin, also known as Examorelin, is a synthetic peptide containing six amino acids. It belongs to the class of growth hormone-releasing peptides (GHRPs) and shares similarities in action with the peptide GHRP-6. Ghrelin, a natural peptide consisting of 28 amino acids, is recognized by scientists for its role in stimulating the release of growth hormone. Over 25 years ago, researchers developed several synthetic compounds, including Hexarelin, to explore their potential to mimic the actions of ghrelin. Ongoing studies and research have been conducted to comprehensively understand the actions and potential of these peptides.

Overview

A study was carried out using infant and adult rats to delve into the mechanisms of Hexarelin. In this research, 10-day-old pups were rendered passive to the natural growth hormone-releasing hormone (GHRH) from birth and subsequently treated with Hexarelin twice a day for 3 to 10 days. The peptide was observed to elevate growth hormone levels in the plasma of these young subjects. Additionally, adult male rats underwent the surgical removal of their anterior pituitary tissue, specifically the mediobasal hypothalamus. These operated rats received Hexarelin twice a day for 5 days prior to surgery. During this period, the peptide did not exhibit significant changes in growth hormone concentrations, according to the study results. However, when these operated rats were exposed to GHRH, it appeared to induce high levels of growth hormones within 7 days after the operation. After 30 days, both Hexarelin and GHRH were found to induce similar increases in plasma hormone levels.

This study led researchers to propose that Hexarelin may operate through three distinct mechanisms:

(a) Potentially acting on the pituitary gland,

(b) Stimulating GHRH release,

(c) Releasing an unidentified hypothalamic factor that could trigger GH release into the plasma.

Similar to other growth hormone-releasing peptides (GHRPs), Hexarelin is believed to stimulate the release of prolactin and adrenocorticotropin (ACTH) hormones. To further comprehend Hexarelin’s mechanism, a clinical study was conducted on seven subjects who were administered Hexarelin, corticotropin-releasing hormone (CRH), or arginine, either individually or in various combinations. The analysis indicated that each of these compounds individually seemed to increase ACTH hormone levels, with all three demonstrating similar potential. When combined, CRH and arginine exhibited synergistic effects, but when combined with Hexarelin, no significant changes in ACTH release were observed.

Research and Clinical Studies

Hexarelin Peptide and Growth Hormone Release 

In this clinical study, the impact of Hexarelin on growth hormone (GH) release was examined in three groups of subjects: pubertal (six subjects), prepubertal (six subjects), and adult (12 subjects aged 22 to 30 years), as well as elderly (12 subjects aged 53 to 79 years) individuals. Subjects were administered Hexarelin alone, GHRH alone, or a combination of GHRH with arginine. In prepubertal children, the combination of GHRH and arginine appeared to elevate GH levels, while Hexarelin alone did not significantly affect GH levels. In contrast, Hexarelin induced higher GH levels compared to GHRH alone and the GHRH + arginine combination in pubertal and adult subjects. Among elderly subjects, Hexarelin was found to induce higher GH levels than GHRH, though GH levels remained lower than those induced by the GHRH + arginine combination. These findings suggest that Hexarelin may elevate GH levels in pubertal and adult subjects, with limited effects in elderly and prepubertal subjects.

Hexarelin’s Impact on GH1 Cell Lines

This study aimed to assess the influence of Hexarelin on GH1 rat tumor cell lines, which are typically insensitive to GHRH. Additionally, researchers investigated the involvement of GHRH in Hexarelin’s actions on GH1 rat cells. Both normal control rat cells and GH1 rat cells were exposed to Hexarelin and GHRH. The results showed that GHRH increased GH levels in the control rat cells but had no discernible effect on GH1 cells. Furthermore, the administration of Hexarelin did not appear to alter GH release in the presence of GHRH. These outcomes suggest that GHRPs and GHRHs may act on distinct cellular sites, and GHRPs like Hexarelin have the potential to influence cells insensitive to GHRH effects.

Hexarelin’s Impact on Cardiovascular Activities

Clinical investigations have suggested that acute administration of Hexarelin may lead to positive inotropic activity in the cardiovascular system. In a study involving seven male subjects, Hexarelin reportedly increased the left ventricular ejection fraction (LVEF) without significantly affecting blood pressure. In a separate study with 24 male subjects with coronary artery disease undergoing surgery under anesthesia, Hexarelin was found to increase cardiac output and arterial pressure while maintaining heart rate. Moreover, when tested on ischemic rat hearts, Hexarelin seemingly restored electrophysiological properties of heart cells, reduced cell apoptosis, and exhibited positive inotropic activity while promoting heart cell survival.

Another study administered Hexarelin daily to male rat hearts with experimentally induced myocardial infarction. The results indicated that Hexarelin increased stroke volume, cardiac output, and decreased peripheral resistance.

Hexarelin’s Impact on Body Composition

This clinical study aimed to investigate gender-related differences in body composition concerning Hexarelin’s potential to stimulate GH release. The study included 28 subjects of both genders aged 60 to 81 years, who were administered Hexarelin. Analysis of blood samples suggested that the peak release of growth hormone was inversely correlated with fat mass. Increased fat mass appeared to lead to reduced GH release, while gender did not significantly impact GH release.

CAS Number
PubChem CID
Molecular Weight
Molecular Formula
Synonyms
Storage (Lyophilized) At 39 Fahrenheit: 2 years At -4 Fahrenheit: 3 years

Hexarelin (5mg / 10mg)

Hexarelin, also known as Examorelin, is a synthetic peptide containing six amino acids. It belongs to the class of growth hormone-releasing peptides (GHRPs) and shares similarities in action with the peptide GHRP-6. Ghrelin, a natural peptide consisting of 28 amino acids, is recognized by scientists for its role in stimulating the release of growth hormone. Over 25 years ago, researchers developed several synthetic compounds, including Hexarelin, to explore their potential to mimic the actions of ghrelin. Ongoing studies and research have been conducted to comprehensively understand the actions and potential of these peptides.

Overview

A study was carried out using infant and adult rats to delve into the mechanisms of Hexarelin. In this research, 10-day-old pups were rendered passive to the natural growth hormone-releasing hormone (GHRH) from birth and subsequently treated with Hexarelin twice a day for 3 to 10 days. The peptide was observed to elevate growth hormone levels in the plasma of these young subjects. Additionally, adult male rats underwent the surgical removal of their anterior pituitary tissue, specifically the mediobasal hypothalamus. These operated rats received Hexarelin twice a day for 5 days prior to surgery. During this period, the peptide did not exhibit significant changes in growth hormone concentrations, according to the study results. However, when these operated rats were exposed to GHRH, it appeared to induce high levels of growth hormones within 7 days after the operation. After 30 days, both Hexarelin and GHRH were found to induce similar increases in plasma hormone levels.

This study led researchers to propose that Hexarelin may operate through three distinct mechanisms:

(a) Potentially acting on the pituitary gland,

(b) Stimulating GHRH release,

(c) Releasing an unidentified hypothalamic factor that could trigger GH release into the plasma.

Similar to other growth hormone-releasing peptides (GHRPs), Hexarelin is believed to stimulate the release of prolactin and adrenocorticotropin (ACTH) hormones. To further comprehend Hexarelin’s mechanism, a clinical study was conducted on seven subjects who were administered Hexarelin, corticotropin-releasing hormone (CRH), or arginine, either individually or in various combinations. The analysis indicated that each of these compounds individually seemed to increase ACTH hormone levels, with all three demonstrating similar potential. When combined, CRH and arginine exhibited synergistic effects, but when combined with Hexarelin, no significant changes in ACTH release were observed.

Research and Clinical Studies

Hexarelin Peptide and Growth Hormone Release 

In this clinical study, the impact of Hexarelin on growth hormone (GH) release was examined in three groups of subjects: pubertal (six subjects), prepubertal (six subjects), and adult (12 subjects aged 22 to 30 years), as well as elderly (12 subjects aged 53 to 79 years) individuals. Subjects were administered Hexarelin alone, GHRH alone, or a combination of GHRH with arginine. In prepubertal children, the combination of GHRH and arginine appeared to elevate GH levels, while Hexarelin alone did not significantly affect GH levels. In contrast, Hexarelin induced higher GH levels compared to GHRH alone and the GHRH + arginine combination in pubertal and adult subjects. Among elderly subjects, Hexarelin was found to induce higher GH levels than GHRH, though GH levels remained lower than those induced by the GHRH + arginine combination. These findings suggest that Hexarelin may elevate GH levels in pubertal and adult subjects, with limited effects in elderly and prepubertal subjects.

Hexarelin’s Impact on GH1 Cell Lines

This study aimed to assess the influence of Hexarelin on GH1 rat tumor cell lines, which are typically insensitive to GHRH. Additionally, researchers investigated the involvement of GHRH in Hexarelin’s actions on GH1 rat cells. Both normal control rat cells and GH1 rat cells were exposed to Hexarelin and GHRH. The results showed that GHRH increased GH levels in the control rat cells but had no discernible effect on GH1 cells. Furthermore, the administration of Hexarelin did not appear to alter GH release in the presence of GHRH. These outcomes suggest that GHRPs and GHRHs may act on distinct cellular sites, and GHRPs like Hexarelin have the potential to influence cells insensitive to GHRH effects.

Hexarelin’s Impact on Cardiovascular Activities

Clinical investigations have suggested that acute administration of Hexarelin may lead to positive inotropic activity in the cardiovascular system. In a study involving seven male subjects, Hexarelin reportedly increased the left ventricular ejection fraction (LVEF) without significantly affecting blood pressure. In a separate study with 24 male subjects with coronary artery disease undergoing surgery under anesthesia, Hexarelin was found to increase cardiac output and arterial pressure while maintaining heart rate. Moreover, when tested on ischemic rat hearts, Hexarelin seemingly restored electrophysiological properties of heart cells, reduced cell apoptosis, and exhibited positive inotropic activity while promoting heart cell survival.

Another study administered Hexarelin daily to male rat hearts with experimentally induced myocardial infarction. The results indicated that Hexarelin increased stroke volume, cardiac output, and decreased peripheral resistance.

Hexarelin’s Impact on Body Composition

This clinical study aimed to investigate gender-related differences in body composition concerning Hexarelin’s potential to stimulate GH release. The study included 28 subjects of both genders aged 60 to 81 years, who were administered Hexarelin. Analysis of blood samples suggested that the peak release of growth hormone was inversely correlated with fat mass. Increased fat mass appeared to lead to reduced GH release, while gender did not significantly impact GH release.

CAS Number 
PubChem CID 
Molecular Weight 
Molecular Formula 
Synonyms 
Storage (Lyophilized)

At 39 Fahrenheit: 2 years

At -4 Fahrenheit: 3 years

Additional information
Size

5mg, 10mg

Related products